Jump to Main Contents

Home > Organization > Section of Experimental Animals (Kashiwa) > Yoshikatsu KOGA, MD, PhD

Yoshikatsu KOGA, MD, PhD


Official Title

  • Head, Section of Experimental Animals/Research Scientist, Division of Developmental Therapeutics

Area of research

  • Tumor Diagnostics
  • Molecular Biology
  • Gastroenterological Surgery


  • Cancer screening
  • Early detection
  • Exfoliated cancer cells
  • Drug delivery system (DDS)

Current main research theme

  • Investigation of fecal RNA test using naturally evacuated feces
  • Development of novel cancer diagnostic method by highly sensitive protein detection system
  • Preclinical study of antibody drug conjugate (ADC) and antibody/drug conjugated micelle (ADCM)

Collaborative research themes

Early diagnosis of cancer using excretion
Preclinical study of second generation DDS drugs


ykoga●east.ncc.go.jp(Replace ● to @)

Brief History

  • 1993-1999  Kumamoto University, Medical School, MD
  • 2003-2009  Kumamoto University Graduate School of Medicine, PhD

  • 1999-2000  Kumamoto University Hospital, Resident
  • 2000-2002  Miyazaki Prefectural Nobeoka Hospital, Surgeon
  • 2002-2003  Minamata Medical Center Hospital, Surgeon
  • 2003-2006  Kumamoto University Hospital, Surgeon
  • 2006-2009  National Cancer Center Hospital East, Research Resident of Investigative Treatment Division
  • 2009-2011  National Cancer Center Hospital East, Research Fellow of Division of Developmental Therapeutics
  • 2011-         National Cancer Center, Section Head of Experimental Animals


  • National Board of Medicine
  • Japanese Board of Surgery
  • Japanese Board of Gastroenterology
  • Japanese Board of Gastroenterological Endoscopy
  • Japanese Board of Hepatology
  • Japanese Board of Gastrointestinal Cancer Screening

 Major affiliated societies

  • Japan Surgical Society
  • Japanese Society of Gastroenterological Surgery
  • Japanese Society of Gastroenterology
  • Japan Gastroenterological Endoscopy Society
  • Japan Society of Clinical Oncology
  • Japan Society of Hepatology
  • Japanese Cancer Association
  • Japan Society of Drug Delivery System
  • Japanese Society of Gastrointestinal Cancer Screening
  • American Association for Cancer Research


  1. Yamazaki N, Koga Y, Taniguchi H, Kojima M, Kanemitsu Y, Saito N, Matsumura Y. High expression of miR-181c as a predictive marker of recurrence in stage II colorectal cancer. Oncotarget 8(4):6970-6983, 2017.
  2. Koga Y, Manabe S, Aihara Y, Sato R, Tsumura R, Iwafuji H, Furuya F, Fuchigami H, Fujiwara Y, Hisada Y, Yamamoto Y, Yasunaga M, Matsumura Y. Antitumor effect of anti-tissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts. Int J Cancer 137(6):1457-1466, 2015.
  3. Koga Y, Yamazaki N, Yamamoto Y, Yamamoto S, Saito N, Kakugawa Y, Otake Y, Matsumoto M, Matsumura Y. Fecal miR-106a is a useful marker for colorectal cancer patients with false-negative results in immunochemical fecal occult blood test. Cancer Epidemiol Biomarker Prev 22(10):1844-1852, 2013.
  4. Koga Y, Yasunaga M, Takahashi A, Kuroda J, Moriya Y, Akasu T, Fujita S, Yamamoto S, Baba H, Matsumura Y. MicroRNA expression profiling of exfoliated colonocytes isolated from feces for colorectal cancer screening. Cancer Prev Res 3(11):1435-1442, 2010.
  5. Koga Y, Yasunaga M, Moriya Y, Akasu T, Fujita S, Yamamoto S, Kozu T, Baba H, Matsumura Y. Detection of colorectal cancer cells from feces using quantitative real-time RT-PCR for colorectal cancer diagnosis. Cancer Sci 99(10): 1977–1983, 2008.